Eli Lilly said patients taking its obesity drug Zepbound lost 47% more weight than those who were given Novo Nordisk's Wegovy ...

Eli Lilly said its weight loss drug Zepbound led to 47% greater weight reduction than rival medicine Wegovy, made by Novo ...

SURMOUNT-5’s results reflect those of multiple real-world studies, which have found that tirzepatide treatment results in ...

After a stellar FY24 performance, Natco Pharma’s stock has taken a hit. What’s next for the company as it faces crucial ...

Novo Nordisk, the Danish company that makes diabetes drug Ozempic and obesity treatment Wegovy, has begun work on a 5.3ha ...

Adults taking Zepbound lost 47% more weight on average than those taking Wegovy, according to clinical trial data from ...

With the purchase of a plant in the Czech Republic, Novo Nordisk is saying “jak se máš” to hundreds of new employees—and ...

Zepbound, the new GLP-1 weight-loss drug from Eli Lilly & Co., has outperformed its main competitor, Wegovy, in a clinical ...

Zepbound, a drug with the main active ingredient tirzepatide, was found to be more helpful in helping people lose weight than ...

On Nov. 26, the Biden administration announced a plan to require Medicare and Medicaid to cover weight loss medications like ...